Results 11 to 20 of about 30,028 (235)

Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.

JAMA
Importance Persons with heterozygous familial hypercholesterolemia (HeFH) are at increased risk of atherosclerotic cardiovascular disease due to lifelong elevated levels of low-density lipoprotein cholesterol (LDL-C).
Ballantyne CM, Gellis L, Tardif JC, Banka P, Navar AM, Asprusten EA, Scott R, Stroes ESG, Froman S, Mendizabal G, Wang F, Catapano AL.   +11 more
europepmc   +2 more sources

Failure of lipid control by PCSK9 inhibitors in compound heterozygous familial hypercholesterolemia complicated with premature myocardial infarction: A case report. [PDF]

Clin Case Rep
A certain level of low‐density lipoprotein receptor activity is crucial for the efficacy of PCSK9i. Therapeutic strategies for familial hypercholesterolemia patients should consider drug efficacy, and genetic testing will be helpful.
Zhang Z, Yang R, Zhu J, Yang X, Luo H, Wang H, Luo X.   +6 more
europepmc   +2 more sources

Genetic and Clinical Characteristics of Patients With Homozygous and Compound Heterozygous Familial Hypercholesterolemia From Three Different Populations: Case Series

Frontiers in Genetics, 2020
Homozygous familial hypercholesterolemia (HoFH) and compound heterozygous familial hypercholesterolemia (cHeFH) are rare disorders generated by disease-causing variants in both alleles of the LDLR or other familial hypercholesterolemia (FH)-related genes.
Tatiana Marusic, Ursa Sustar, Fouzia Sadiq, Vjosa Kotori, Matej Mlinaric, Jernej Kovac, Saeed Shafi, Iqbal Khan, Iqbal Khan, Matija Cevc, Katarina Trebusak Podkrajsek, Katarina Trebusak Podkrajsek, Tadej Battelino, Tadej Battelino, Urh Groselj, Urh Groselj   +15 more
doaj   +2 more sources

Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.

JAMA Pediatr
Key Points Question Is alirocumab an efficacious lipid-lowering therapy (LLT) for pediatric patients (8-17 years) with heterozygous familial hypercholesterolemia (HeFH) inadequately controlled with statins?
Santos RD, Wiegman A, Caprio S, Cariou B, Averna M, Poulouin Y, Scemama M, Manvelian G, Garon G, Daniels S.   +9 more
europepmc   +2 more sources

PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study

Journal of Clinical Lipidology, 2020
BACKGROUND Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder characterized by elevated levels of low-density lipoprotein cholesterol (LDL-C).
Stephen R Daniels, Sonia Caprio, Umesh Chaudhari   +2 more
exaly   +2 more sources

Awareness and knowledge of heterozygous familial hypercholesterolemia among Serbian pediatricians [PDF]

Frontiers in Pediatrics, 2023
ObjectivePublished reports describing awareness and knowledge of familial hypercholesterolemia (FH) among pediatricians are few and differ considerably across countries.
Ljiljana Bjelakovic, Lazar Stosic, Aleksandra Klisic, Marko Jovic, Sanja Stankovic, Aleksandra Stankovic, Sasa Pantelic, Danijela Zivkovic, Vladimir Vukovic, Vladimir Vukovic, Bojko Bjelakovic   +10 more
doaj   +2 more sources

Correlates of Coronary Artery Calcification Prevalence and Severity in Patients With Heterozygous Familial Hypercholesterolemia. [PDF]

CJC Open, 2021
Background Determinants of coronary artery calcification (CAC) prevalence and severity in heterozygous familial hypercholesterolemia (HeFH) remain understudied.
Drouin-Chartier JP, Tremblay AJ, Godbout D, Gagnon A, Clavel MA, Clisson M, Arsenault BJ, Pibarot P, Larose É, Couture P.   +9 more
europepmc   +2 more sources

Two Cases of Heterozygous Familial Hypercholesterolemia in Children Effectively Managed With Pitavastatin and Ezetimibe Combination Therapy [PDF]

Clinical Case Reports
Heterozygous familial hypercholesterolemia (HeFH) strongly predisposes individuals to atherosclerosis, including coronary artery disease, leading to death from cardiovascular diseases in > 60% of untreated cases.
Katsufumi Nishioka, Sonoko Kondo, Kanako Irie, Takeo Kondo, Takashi Iwase, Ryosuke Tani, Tomoko Inoue, Keiji Matsunaga, Tetsuo Minamino, Takashi Kusaka   +9 more
doaj   +2 more sources

Triple Assessments of Atherosclerosis in Patients With Heterozygous Familial Hypercholesterolemia. [PDF]

JACC Asia
Data on the appropriate timing and impact of atherosclerosis assessment in patients with heterozygous familial hypercholesterolemia (HeFH) are limited.The authors aimed to determine when atherosclerotic changes occur and the utility of triple assessments of carotid plaque, coronary plaque, and coronary artery calcium (CAC) in patients with HeFH.Data ...
Tada H, Kojima N, Yamagami K, Nomura A, Nohara A, Usui S, Sakata K, Kawashiri MA, Takamura M.   +8 more
europepmc   +4 more sources

Assessments of Atherosclerosis and Treatment Strategies for Heterozygous Familial Hypercholesterolemia. [PDF]

J Atheroscler Thromb
Patients with familial hypercholesterolemia (FH) carry an extremely elevated cardiovascular risk because of lifelong exposure to elevated low-density lipoprotein cholesterol (LDL-C). The Japan Atherosclerosis Society (JAS) complies with the clinical guidelines of FH stipulating diagnostic criteria as well as the treatment targets based on their ...
Tada H, Harada-Shiba M.
europepmc   +4 more sources